Nektar beats estimates but shares fall 4% on annual decline
Revenue drops 25% YoY following Huntsville facility sale, offset by strong clinical data and February financing
Nektar Therapeutics shares fell 4% on Thursday despite the biotechnology company beating both earnings and revenue expectations for the fourth quarter, as investors focused on a year-over-year revenue decline that stemmed from a strategic asset sale.
The San Francisco-based company reported a loss of $1.78 per share for the quarter, significantly narrower than the $2.79 loss analysts had anticipated. Revenue reached $21.8 million, more than double the $10.2 million consensus estimate, according to the company's earnings release. However, the stock dropped as quarterly revenue declined 25% from $29.2 million in the same period last year.
The year-over-year contraction reflects the impact of Nektar's sale of its Huntsville, Alabama manufacturing facility, a transaction that reduces the company's asset base but strengthens its financial position. The strategic move comes amid broader restructuring efforts by biotechnology companies to preserve cash and focus resources on high-potential therapeutic programs.
Despite the near-term revenue headwind, Nektar secured $460 million in financing during February, providing substantial runway to advance its clinical pipeline. The capital raise underscores continued institutional confidence in the company's lead program, rezpegaldesleukin, an interleukin-2 cytokine currently in development for atopic dermatitis and other inflammatory conditions.
Recent Phase 2 clinical data for rezpegaldesleukin has shown encouraging results, positioning the drug as a potential treatment option for patients with moderate-to-severe atopic dermatitis who have inadequate responses to existing therapies. The company has announced plans to initiate a Phase 3 study for the indication in June 2026, a critical milestone that could determine the program's commercial viability.
Analysts maintain an optimistic outlook on Nektar's prospects, with an average price target of $129.86, representing substantial upside from the current trading level of approximately $70.36. The stock has received overwhelmingly positive ratings from sell-side analysts, with 8 analysts recommending either buy or strong buy and none suggesting investors sell or hold shares.
The company's market capitalization stands at $2.02 billion, reflecting investor anticipation for rezpegaldesleukin's progress despite current commercial limitations. Nektar's 52-week trading range shows remarkable volatility, with shares touching a low of $6.48 and surging to a high of $75.67, highlighting the stock's sensitivity to clinical development news.
Institutional investors hold approximately 64% of outstanding shares, while insider ownership remains modest at 0.6%. The company's financial metrics show the challenges typical of clinical-stage biotechnology firms, with negative profit margins and a return on equity of -180%, though these figures are expected to improve if rezpegaldesleukin successfully advances through late-stage trials.
The divergence between Nektar's earnings beat and its stock performance illustrates the complex calculation investors make when evaluating biotechnology companies. While the quarterly results exceeded Wall Street expectations, the decision to monetize the Huntsville facility signals a longer timeline to revenue generation, requiring investors to look past near-term financial metrics toward clinical catalysts still more than a year away.
As Nektar prepares for the Phase 3 study launch in June 2026, investors will be watching for interim data readouts, regulatory interactions, and updates on trial enrollment as key drivers of share performance. The company's ability to execute efficiently on clinical development while managing its cash burn will determine whether current analyst optimism translates into commercial success.